Molecules in medicine mini-review: isoforms of PI3K in biology and disease

Journal of Molecular Medicine

Volumn 94, Issue 1, 2016, Pages 5-11

  Vanhaesebroeck, Bart ^a   Whitehead, Maria A ^a   Piñeiro, Roberto ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Cancer; Diabetes; Immunity; Inflammation; Metabolic syndrome; Obesity; Overgrowth syndrome; Pharmacological inhibitor; PI3K; Signalling; Vesicular traffic

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; ISOPROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

AUTOIMMUNITY; CANCER CELL; CARDIOVASCULAR DISEASE; ENZYME ACTIVE SITE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GROWTH DISORDER; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; OVERGROWTH SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SYNDROME; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS; PHOSPHORYLATION;

CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; INFLAMMATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84953638651     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-015-1352-5     Document Type: Review

References (71)

1. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005) Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30(4):194–204
2. Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A (2009) Twice upon a time: PI3K’s secret double life exposed. Trends Biochem Sci 34(5):244–248
3. Alliouachene S, Bilanges B, Chicanne G, Anderson KE, Pearce W, Ali K, Valet C, Posor Y, Low PC, Chaussade C et al (2015) Inactivation of the class II PI3K-C2β potentiates insulin signaling and sensitivity. Cell Reports accepted for publication
4. Bilanges B, Vanhaesebroeck B (2014) Cinderella finds her shoe: the first Vps34 inhibitor uncovers a new PI3K-AGC protein kinase connection. Biochem J 464(2):e7–e10
5. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A 109(38):15259–15264
6. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP et al (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 90(6):1108–1115
7. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE et al (2012) Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44(8):928–933
8. Riviere JB, Mirzaa GM, O’Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM et al (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44(8):934–940
9. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A et al (2012) De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 44(8):941–945
10. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E et al (2014) Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A 164(7):1713–1733
11. Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I et al (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525(7567):119–123
12. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O et al (2015) PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525(7567):114–118
13. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A et al (2014) Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 13(5):1117–1129
14. Weigelt B, Downward J (2012) Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol 2:109
15. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091):366–370
16. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733–747
17. Foukas LC, Bilanges B, Bettedi L, Pearce W, Ali K, Sancho S, Withers DJ, Vanhaesebroeck B (2013) Long-term p110alpha PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med 5(4):563–571
18. Ortega-Molina A, Lopez-Guadamillas E, Mattison JA, Mitchell SJ, Munoz-Martin M, Iglesias G, Gutierrez VM, Vaughan KL, Szarowicz MD, Gonzalez-Garcia I et al (2015) Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys. Cell Metab 21(4):558–570
19. Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K (2010) The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 3(134):ra60
20. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y et al (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11(5):507–514
21. Giordanetto F, Wallberg A, Ghosal S, Iliefski T, Cassel J, Yuan ZQ, von Wachenfeldt H, Andersen SM, Inghardt T, Tunek A et al (2012) Discovery of phosphoinositide 3-kinases (PI3K) p110beta isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyri midin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. Bioorg Med Chem Lett 22(21):6671–6676
22. Nylander S, Wagberg F, Andersson M, Skarby T, Gustafsson D (2015) Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase beta inhibition and aspirin in man. J Thromb Haemost 13(8):1494–1502
23. Laurent PA, Severin S, Gratacap MP, Payrastre B (2014) Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Adv Biol Regul 54:162–174
24. Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG (2015) Oncogenic activation of the PI3-kinase p110beta isoform via the tumor-derived PIK3Cbeta kinase domain mutation. Oncogene
25. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228
26. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P et al (2009) Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16(6):463–474
27. Berenjeno IM, Guillermet-Guibert J, Pearce W, Gray A, Fleming S, Vanhaesebroeck B (2012) Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 442(1):151–159
28. Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111(17):6395–6400
29. Jiang X, Chen S, Asara JM, Balk SP (2010) Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 285(20):14980–14989
30. Zhu Q, Youn H, Tang J, Tawfik O, Dennis K, Terranova PF, Du J, Raynal P, Thrasher JB, Li B (2008) Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27(33):4569–4579
31. Guillermet-Guibert J, Smith LB, Halet G, Whitehead MA, Pearce W, Rebourcet D, Leon K, Crepieux P, Nock G, Stromstedt M et al (2015) Novel role for p110beta PI 3-kinase in male fertility through regulation of androgen receptor activity in Sertoli cells. PLoS Genet 11(7):e1005304
32. Marques RB, Aghai A, de Ridder CM, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J et al (2015) High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur Urol 67(6):1177–1185
33. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J et al (2015) Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell 27(1):109–122
34. Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, Hirose M, Juss J, Oxley D, Chessa TA et al (2011) PI3Kbeta plays a critical role in neutrophil activation by immune complexes. Sci Signal 4(168):ra23
35. Leverrier Y, Okkenhaug K, Sawyer C, Bilancio A, Vanhaesebroeck B, Ridley AJ (2003) Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem 278(40):38437–38442
36. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94(9):4330–4335
37. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, Cooper JA, Hoekstra MF (1997) p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 272(31):19236–19241
38. Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, Starkey ML, Bilancio A, Need AC, Smith AJ, Hall SM et al (2007) Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS ONE 2(9):e869
39. Sawyer C, Sturge J, Bennett DC, O’Hare MJ, Allen WE, Bain J, Jones GE, Vanhaesebroeck B (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63(7):1667–1675
40. Tzenaki N, Andreou M, Stratigi K, Vergetaki A, Makrigiannakis A, Vanhaesebroeck B, Papakonstanti EA (2012) High levels of p110delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110delta inhibitors through PTEN activation. FASEB J 26(6):2498–2508
41. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD et al (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (NY) 297(5583):1031–1034
42. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E et al (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011):1007–1011
43. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP et al (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440
44. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C et al (2013) Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science (NY) 342(6160):866–871
45. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 15(1):88–97
46. Coulter T, Chandra A, Bacon CM, Babar J, Curtis J, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H et al (2015) The broad clinical spectrum and unexpected features of Activated PI3-kinase delta syndrome; large patient cohort study. Submitted for publication
47. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G et al (2013) Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 110(4):1398–1403
48. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B et al (2015) Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 27(1):97–108
49. Peng J, Awad A, Sar S, Hamze Komaiha O, Moyano R, Rayal A, Samuel D, Shewan A, Vanhaesebroeck B, Mostov K et al (2015) Phosphoinositide 3-kinase p110delta promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization. Nat Commun 6:5937
50. Tzenaki N, Papakonstanti EA (2013) p110delta PI3 kinase pathway: emerging roles in cancer. Front Oncol 3:40
51. Vanhaesebroeck B, Khwaja A (2014) PI3Kdelta inhibition hits a sensitive spot in B cell malignancies. Cancer Cell 25(3):269–271
52. Okkenhaug K, Burger JA (2015) PI3K signaling in normal b cells and chronic lymphocytic leukemia (CLL). Curr Top Microbiol Immunol
53. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H et al (2014) Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510(7505):407–411
54. Hawkins PT, Stephens LR (2015) PI3K signalling in inflammation. Biochim Biophys Acta 1851(6):882–897
55. Costa C, Martin-Conte EL, Hirsch E (2011) Phosphoinositide 3-kinase p110gamma in immunity. IUBMB Life 63(9):707–713
56. Ruckle T, Schwarz MK, Rommel C (2006) PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’? Nat Rev Drug Discov 5(11):903–918
57. Ghigo A, Morello F, Perino A, Hirsch E (2013) Therapeutic applications of PI3K inhibitors in cardiovascular diseases. Future Med Chem 5(4):479–492
58. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W et al (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19(6):715–727
59. Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O’Brien SM, Pagel JM, Poleski MH et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 1–8
60. Wilson R, Cahn A, Deans A, McSherry I, Rambaran C, Sousa A, Wilbraham D (2013) Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy male subjects in a phase I study. ERJ 42(57)
61. Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, Burrows P, Frieden IJ, Garzon MC, Lopez-Gutierrez JC et al (2015) Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics 136(1):e203–e214
62. Okkenhaug K (2013) Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 31:675–704
63. Banham-Hall E, Clatworthy MR, Okkenhaug K (2012) The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 6:245–258
64. So L, Fruman DA (2012) PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 442(3):465–481
65. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM et al (2013) PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 20(11):1364–1374
66. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 107(25):11381–11386
67. Rehman FL, Lord CJ, Ashworth A (2012) The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov 2(11):982–984
68. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X et al (2014) CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26(1):136–149
69. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P et al (2015) PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 7(283):283ra251
70. Graupera M, Potente M (2013) Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res 319(9):1348–1355
71. Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ (2012) Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 18(1):161–169